Visiting Professor of Pharmacology, Department of Medicine.
Until retirement in April 2008 Professor Hill was Executive Director, Licensing and External Research, Europe for Merck, Sharp and Dohme Research Laboratories. He worked in the pharmaceutical industry for over 25 years. Between 1997 and 2002 he had oversight responsibility for Neuroscience research at the MSD / Banyu Research Labs in Tsukuba, Japan. At Merck he chaired discovery project teams responsible for the marketed products Maxalt® and Emend®.
Dr. Hill is a non-executive director (NED) and Chairman of Avilex (a spin out company from the University of Copenhagen developing a novel neuroprotective treatment for stroke) and a NED of Addex ( a publicly quoted Swiss company discovering and developing treatments for CNS disorders). He has also served on the Boards of Covagen (until its sale to J&J in Sept 2014), Orexo AB and Asceneuron. He is Currently Chair of the Scientific Advisory Board at Asceneuron. He is Visiting Industrial Professor of Pharmacology in the University of Bristol. Dr Hill received BPharm and PhD degrees from the University of London and was elected to Fellowship of the Academy of Medical Sciences in 2005 . He was a lecturer in Pharmacology at the University of Bristol School of Medicine from 1974 to 1983. He is President Emeritus of the British Pharmacological Society, has been a Council Member of the Academy of Medical Sciences and served on the UK Advisory Council on Misuse of Drugs until 2019.
Telephone: 44 (0)7872 850 331
et al., 2021, Functional evaluation of NK1 antagonism on cue reactivity in opiate dependence; an fMRI study, Drug and Alcohol Dependence, Vol:221, ISSN:0376-8716, Pages:1-7